HematologyNews.net

Hematology Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Cardiobase

Search results for "Brentuximab Vedotin"

Survival data from two Brentuximab vedotin ( Adcetris ) pivotal Phase 2 clinical trials in relapsed / refractory Hodgkin lymphoma ( R/R HL ) and relapsed / refractory systemic anaplastic large cell ly ...


Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, has achieved an overall response rate of 66%, as assessed by International Harmonization Project response criteria ( n=19/29: 95% CI, 46-82 ), in tran ...


The findings from KEYNOTE-087, the phase 2 study investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, as a monotherapy in patients with relapsed or refractory classical Hodgkin l ...


PD-1 blockade via Pembrolizumab ( Keytruda ) monotherapy has shown antitumor activity in relapsed or refractory classic Hodgkin lymphoma ( R/R cHL ). KEYNOTE-204 was a randomized, international, o ...